ABSTRACT Ten patients with exercise induced asthma, in whom inhaled nedocromil sodium 4 mg by metered dose inhaler attenuated the exercise fall in forced expiratory volume in one second (FEV1) by at least 40%, participated in a double blind dose response study to compare the protective effect of nedocromil sodium given 15 minutes before exercise challenge via a nebuliser (Wright) in concentrations of0 5, 5, 10, and 20 mg/ml with that ofplacebo (saline). Response was assessed as the maximum fall in FEV, after the patient had run on a treadmill for six to eight minutes. Plasma concentrations ofnedocromil sodium were measured at the time ofchallenge. After exercise challenge the mean (SEM) maximum percentage falls in FEV, were 30 3 (1 6) for the control run and 28-0 (4-1) after placebo. The percentage fall was attenuated by pretreatment with all concentrations of nedocromil sodium to 12-8 (2-8), 112 (2-1), 12-8 (2 1), and 14-1 (3-5) for the 0 5, 5, 10, and 20 mg/ml concentrations respectively (p < 0 001). There were no significant differences between the different nedocromil concentrations. Mean plasma concentrations of nedocromil were proportional to dose. Thus concentrations ofnebulised nedocromil sodium that ranged from 0 5 to 20 mg/ml gave a similar degree of protection (50-60%) against exercise induced asthma. This appears to be the maximum protection that can be achieved with nedocromil sodium and is similar to the protection obtained with 4 mg nedocromil administered by metered dose aerosol.
Introduction
Nedocromil sodium is the salt of a pyranoquinoline dicarboxylic acid that has been developed for the treatment of reversible obstructive airways disease.'2 It is thought to reduce inflammation. 2 In vitro it prevents the release of histamine and other mediators from lung mast cells3 and in asthmatic patients inhalation of 4 mg nedocromil sodium is effective in blocking allergen induced bronchoconstriction for at least three4 and possibly up to six hours. 5 The drug also offers partial protection against bronchoconstriction due to sulphur dioxide,6 fog,7 cold air,8 adenosine,9 and exercise.'" In clinical trials 4 mg inhaled nedocromil sodium was more effective than placebo in controlling symptoms and improving lung function in adult asthmatic patients with both twice and four times daily dosing."-'4 Despite numerous studies with various bronchial provocation tests comparatively little is known of the dose-response characteristics of nedocromil sodium.
The aim of the present study was to examine the dose-response characteristics of nedocromil sodium over a range ofconcentrations in patients with exercise induced asthma, a nebulised solution being used to allow greater flexibility in dosing. Plasma concentrations of the drug were measured as a check on absorbed dose.
Methods
Twelve men with extrinsic asthma were screened and 10 of these, aged 17-54 (mean 37, SEM 4) years, were enrolled. The selected patients had previously been shown to have exercise induced asthma with a fall in FEV, ofmore than 20% after exercise challenge. They also had at least 40% protection against the fall following treatment with nedocromil sodium aerosol (4 mg The time course of change in FEV, is shown in the figure. Significant differences between placebo and active treatments were found at all time points after exercise except the first. There were no significant differences between active treatments. The recovery in FEV, was quicker with active treatments than with placebo. Thirty minutes after exercise the FEV, had returned to baseline value after nedocromil whereas with placebo it was still more than 15% below the prechallenge value ( figure) .
The protective effect of nedocromil sodium (4 mg) from a metered dose inhaler was similar to that produced by all the nebulised concentrations and was more than 50% in all cases. The percentage protection was 8-9 (12-0), 58-8 (8 9), 65-0 (6-3), 58-8 (7.7) and 56-7 (9-0) for placebo and the 0 5, 5, 10, and 20 mg/ml nebulised solution.
Nebulised salbutamol was required after challenge by all subjects after the control test; by five after placebo; by one after 0 5 and 20 mg/ml nedocromil; by one after 0 5, 5, and 20 mg/ml; and by another after 10 mg/ml nedocromil. Individual patients showed some variability in response with the occasional unusual result. Such atypical results were not, however, due to variable absorption as the plasma concentrations of nedocromil sodium were consistent and proportional to the dose given. The mean (SEM) plasma concentrations of nedocromil sodium (ng/ml) immediately before exercise challenge were: 0-5 mg/ml-not detectable; 5 mg/ml-2a 1 (0 6); 10 mg/ml-5-9 (1-4); 20 mg/ ml-I 2-8 (2-1); and 4 mg aerosol-2-4 (0-6).
This study shows that nebulised nedocromil sodium administered 15 minutes before exercise challenge to susceptible patients in concentrations from 0 5 mg/ml to 20 mg/ml is effective in attenuating the fall in FEV,, with no significant difference in the inhibitory effect between the four concentrations. Protection was about 50%, which is similar to that afforded by 4 mg nedocromil from a metered dose inhaler. Although there was no difference between the protection afforded by the different nebuliser concentrations, plasma concentrations were related to nebuliser concentration and hence to dose. In this respect 4 mg nedocromil from the metered dose inhaler produced plasma concentrations similar to the 5 mg/ml nebuliser concentration, suggesting that the dose absorbed is similar. Previous studies have shown a protective effect of nedocromil sodium from a metered dose inhaler in exercise challenge. ' 16 In this study the response to nedocromil was not dose dependent over the range of doses studied. This contrasts with earlier observations with sodium cromoglycate in exercise challenge.'7 18 The difference may reflect the fact that nedocromil sodium is more potent than sodium cromoglycate, as shown in some in vitro'9 and in vivo models,202' so that all doses lie near the top of the dose-response curve. Use of lower concentrations 15 minutes before challenge would probably result in a dose related response. Duration of effect might be expected to vary with dose; this is under investigation.
Exercise induced bronchoconstriction is a well recognised phenomenon in asthma and, although the exact mechanism of its pathogenesis is not clear, it provides a relatively safe method for assessing the effect ofvarious drugs. The coefficient ofvariation was calculated to vary from 12% to 16% in a recent study in our department,22 though intrasubject variation has been reported to be as high as 25%. 
